"Big odds and a long long way to go"??
You do understand that Remestemcel is being reviewed by the FDA under Priority-Review and Fast-Track status (incredible confidence by the FDA to give them these designations), with a decision by September at the latest. That's 4 months away, after over a decade of trials that have proven their treatment has a great safety profile and is effective at increasing the survival rates of very sick children. That same treatment is also now only months away from completing a trial that will determine the fate of adults who are otherwise given a 12% chance of survival from Covid-induced ARDS.
4 months in a biotech pipeline is a very very short way to go.
It's a sunny day in Melbourne, your wet blanket attitude should be hung on the line to dry
MSB Trading - 2020, page-11087
-
- There are more pages in this discussion • 12,074 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |